Profiling of circulating free DNA using targeted and genome wide sequencing in patients with Small Cell Lung Cancer.
Small cell lung cancer (SCLC) accounts for ∼250,000 deaths worldwide each year. Acquisition of adequate tumour biopsies is challenging and liquid biopsies present an alternative option for patient stratification and response monitoring. We applied whole genome next-generation sequencing (NGS) to circulating-free DNA (cfDNA) from 39 patients with limited-stage (LS-SCLC) and 30 of patients with extensive-stage (ES-SCLC) to establish genome wide copy number aberrations (CNA) as well as targeted mutation analysis of 110 SCLC associated genes. Quantitative metrics were calculated for CNA including Percent Genome Amplified (PGA; percentage of genomic regions amplified), Z-score (measure of standard deviation) and Moran's I (measure of spatial autocorrelation). In addition CellSearch®, an epitope dependent enrichment platform was used to enumerate circulating tumour cells (CTCs) from a parallel blood sample. Genome-wide and targeted cfDNA sequencing data identified tumour related changes in 94% of patients with LS-SCLC and 100% of patients with ES-SCLC. Parallel analysis of CTCs based on ≥ 1 CTC/7.5ml blood increased tumour detection frequencies to 95% for LS-SCLC. Both CTC counts and cfDNA readouts correlated with disease stage and overall survival (OS). We demonstrate that a simple cfDNA genome wide copy number approach provides an effective means of monitoring patients through treatment and show that targeted cfDNA sequencing identifies potential therapeutic targets in >50% of patients. We are now incorporating this approach in additional studies and trials of targeted therapies.